76 related articles for article (PubMed ID: 11424414)
1. [Capecitabine (Ro09-1978) for therapy of advanced and recurrent gastric cancer].
Koizumi W
Nihon Rinsho; 2001 Apr; 59 Suppl 4():398-403. PubMed ID: 11424414
[No Abstract] [Full Text] [Related]
2. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Koizumi W; Okayasu I; Hyodo I; Sakamoto J; Kojima H;
Anticancer Drugs; 2008 Sep; 19(8):819-24. PubMed ID: 18690094
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Sai-Hong Ignatius Ou and Randall F. Holcombe.
Ou SH; Holcombe RF
Drugs; 2007; 67(4):611-2. PubMed ID: 17352521
[No Abstract] [Full Text] [Related]
4. Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection?
O'Neil BH; McLeod HL
J Clin Oncol; 2006 Sep; 24(25):4051-3. PubMed ID: 16943521
[No Abstract] [Full Text] [Related]
5. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
Seol YM; Song MK; Choi YJ; Kim GH; Shin HJ; Song GA; Chung JS; Cho GJ
Jpn J Clin Oncol; 2009 Jan; 39(1):43-8. PubMed ID: 18997184
[TBL] [Abstract][Full Text] [Related]
6. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
Boskos CS; Liacos C; Korkolis D; Aygerinos K; Lamproglou I; Terpos E; Stoupa E; Baltatzis G; Beroukas K; Papasavvas P; Dimopoulos MA; Bamias A
J Surg Oncol; 2010 Oct; 102(5):408-12. PubMed ID: 19877119
[TBL] [Abstract][Full Text] [Related]
7. Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Gao J; Lu M; Yu JW; Li YY; Shen L
BMC Cancer; 2011 May; 11():177. PubMed ID: 21586171
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine: new indication. Advanced-stage gastric cancer: oral route for some patients. Risk of palmoplantar erythrodysaesthesia.
Prescrire Int; 2008 Jun; 17(95):107. PubMed ID: 18627118
[No Abstract] [Full Text] [Related]
9. [Preliminary study of XELOX regimen as the first-line chemotherapy in advanced or recurrent gastric cancer].
Min N; He BF; Zhang LS; Liao H; Jia YZ
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):599-601. PubMed ID: 20335149
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
Saif MW; Black G; Roy S; Bell D; Russo S; Eloubeidi MA; Steg A; Johnson MR; Zelterman D; Diasio RB
Cancer J; 2007; 13(4):247-56. PubMed ID: 17762760
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
Hattori K; Kohchi Y; Oikawa N; Suda H; Ura M; Ishikawa T; Miwa M; Endoh M; Eda H; Tanimura H; Kawashima A; Horii I; Ishitsuka H; Shimma N
Bioorg Med Chem Lett; 2003 Mar; 13(5):867-72. PubMed ID: 12617910
[TBL] [Abstract][Full Text] [Related]
12. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.
Ishikawa T; Sekiguchi F; Fukase Y; Sawada N; Ishitsuka H
Cancer Res; 1998 Feb; 58(4):685-90. PubMed ID: 9485021
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine in gastric cancer.
Bang YJ
Expert Rev Anticancer Ther; 2011 Dec; 11(12):1791-806. PubMed ID: 22117147
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.
Sawada N; Kondoh K; Mori K
Oncol Rep; 2007 Oct; 18(4):775-8. PubMed ID: 17786335
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Garcia AA; Blessing JA; Lenz HJ; Darcy KM; Mannel RS; Miller DS; Husseinzadeh N;
Gynecol Oncol; 2005 Mar; 96(3):810-7. PubMed ID: 15721430
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of capecitabine in gastric cancer.
Comella P; Franco L; Casaretti R; de Portu S; Menditto E
Pharmacotherapy; 2009 Mar; 29(3):318-30. PubMed ID: 19249950
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
[TBL] [Abstract][Full Text] [Related]
18. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
Fakih MG; Rajput A; Yang GY; Pendyala L; Toth K; Smith JL; Lawrence DD; Rustum YM
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1462-70. PubMed ID: 16750332
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Saif MW; Eloubeidi MA; Russo S; Steg A; Thornton J; Fiveash J; Carpenter M; Blanquicett C; Diasio RB; Johnson MR
J Clin Oncol; 2005 Dec; 23(34):8679-87. PubMed ID: 16314628
[TBL] [Abstract][Full Text] [Related]
20. ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer.
Ryu MH; Kang YK
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1745-51. PubMed ID: 19954285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
